These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Silencing NLRC5 inhibits extracellular matrix expression in keloid fibroblasts via inhibition of transforming growth factor-β1/Smad signaling pathway.
    Author: Ma HL, Zhao XF, Chen GZ, Fang RH, Zhang FR.
    Journal: Biomed Pharmacother; 2016 Oct; 83():1016-1021. PubMed ID: 27525969.
    Abstract:
    Dermal fibrosis is characterized by collagen accumulation and hyperproliferation of fibroblasts. NLRC5, as the largest member of nucleotide-binding domain and leucine-rich repeat (NLRs) family, has recently been implicated in the development of hepatic fibrosis. However, the role of NLRC5 in dermal fibrosis remains unknown. Therefore, herein, we investigated the effects of NLRC5 on keloid fibroblasts (KFs) and transforming growth factor-β1 (TGF-β1)-induced collagen expression and explored the underlying mechanism. We observed that NLRC5 mRNA and protein levels were highly expressed in KFs, silencing NLRC5 greatly suppressed TGF-β1-induced KFs proliferation. Silencing NLRC5 also obviously inhibited the expression of type I collagen, CTGF and α-smooth muscle actin (α-SMA) in human KFs induced by TGF-β1, as well as the expression of TGF-β receptor I and II. Furthermore, silencing NLRC5 suppressed the expression of TGF-β1-induced Smad2 and Smad3 phosphorylation in human KFs. Taken together, our study suggest that silencing NLRC5 reduced ECM expression in KFs through inhibiting the TGF-β1/Smad signaling pathway. Therefore, NLRC5 may represent a promising target for treatment of the keloid disease.
    [Abstract] [Full Text] [Related] [New Search]